Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of cohort. Fisher’s exact test and Chi-square test (as appropriate) were used to generate P-values

From: Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer

Characteristic No. ColXα1 Positive N (%) P-value
No. of patients 164 62.8%  
Age (year) 164  
  < 65 99 57 (57.5%) 0.10
  ≥ 65 65 46 (71%)  
Age (year)
  < 58   61% 0.75
  ≥ 58   64%  
Laterality 164  
 Left 94 54 (57.3%) 0.52
 Right 70 30 (42.7%)  
Foci 164  
 Solitary 146 61.6% 0.45
 Multifocal 18 72.2%  
LVI 130  
 Pos 97 62 (63.9%) 0.005
 Neg 33 21 (63.6%)  
Lymph node status 120   0.21
 N0 64 30 (46.9%)  
 N1 42 26 (61.9%)  
 N2 8 4 (50.0%)  
 N3 6 5 (83.3%)  
Clinical stage 164  
 I 52 61.5% 0.34
 II 87 60.9%  
 III 22 77.3%  
 IV 3 33.3%  
ColXα1 164  
 0 21  
 1 40   
 2 47   
3 56   
Stroma Content 164  
 0 30 15 (50%) 0.024
1 95 57 (60%)  
 2 39 31 (79.5%)  
TILs 164  
 1 (Rare) 22 15 (68.2%) < 0.001
 2 (Low density) 113 82 (72.6%)  
 3 (High density) 29 6 (20.7%)